1. Home
  2. CINGW vs WFCF Comparison

CINGW vs WFCF Comparison

Compare CINGW & WFCF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • WFCF
  • Stock Information
  • Founded
  • CINGW N/A
  • WFCF 1996
  • Country
  • CINGW United States
  • WFCF United States
  • Employees
  • CINGW 13
  • WFCF N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • WFCF Computer Software: Prepackaged Software
  • Sector
  • CINGW Health Care
  • WFCF Technology
  • Exchange
  • CINGW Nasdaq
  • WFCF Nasdaq
  • Market Cap
  • CINGW N/A
  • WFCF N/A
  • IPO Year
  • CINGW 2021
  • WFCF 2011
  • Fundamental
  • Price
  • CINGW $0.04
  • WFCF $11.10
  • Analyst Decision
  • CINGW
  • WFCF
  • Analyst Count
  • CINGW 0
  • WFCF 0
  • Target Price
  • CINGW N/A
  • WFCF N/A
  • AVG Volume (30 Days)
  • CINGW N/A
  • WFCF 2.1K
  • Earning Date
  • CINGW N/A
  • WFCF 05-05-2025
  • Dividend Yield
  • CINGW N/A
  • WFCF N/A
  • EPS Growth
  • CINGW N/A
  • WFCF 2.22
  • EPS
  • CINGW N/A
  • WFCF 0.40
  • Revenue
  • CINGW N/A
  • WFCF $25,746,000.00
  • Revenue This Year
  • CINGW N/A
  • WFCF N/A
  • Revenue Next Year
  • CINGW N/A
  • WFCF N/A
  • P/E Ratio
  • CINGW N/A
  • WFCF $28.67
  • Revenue Growth
  • CINGW N/A
  • WFCF 2.43
  • 52 Week Low
  • CINGW N/A
  • WFCF $9.76
  • 52 Week High
  • CINGW N/A
  • WFCF $13.50
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • WFCF 46.54
  • Support Level
  • CINGW N/A
  • WFCF $10.72
  • Resistance Level
  • CINGW N/A
  • WFCF $11.75
  • Average True Range (ATR)
  • CINGW 0.00
  • WFCF 0.46
  • MACD
  • CINGW 0.00
  • WFCF 0.01
  • Stochastic Oscillator
  • CINGW 0.00
  • WFCF 33.35

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Share on Social Networks: